Publications by authors named "Andrea Schloebe"
Article Synopsis
- Early prediction of therapeutic response in atopic dermatitis (AD) using baricitinib can optimize treatment strategies for patients.
- The study identified early clinical improvements at weeks 2, 4, and 8 that could reliably predict outcomes at week 16, highlighting the importance of composite clinical scores over single parameters.
- Results showed that improvements assessed by combinations of Eczema Area and Severity Index (EASI) and Itch Numeric Rating Scale could strongly predict later clinical response, aiding dermatologists in treatment decision-making.
Background: In adults with atopic dermatitis (AD), head and/or neck involvement is frequent, bothersome, and impacts quality of life, however, long-term topical corticosteroids (TCS) are contraindicated for this difficult-to-treat region. Baricitinib, an oral, selective, reversible inhibitor of Janus kinase 1/2 has demonstrated efficacy in adult patients with moderate-to-severe AD.
Objectives: For this post hoc analysis, data from five Phase III trials were used to investigate the efficacy of baricitinib in patients with head and neck involvement.